Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK1324726A (I-BET726) 是一种选择性有效的BET 蛋白抑制剂,高亲和力结合到BRD2、BRD3和BRD4,IC50值分别为 41 nM、31 nM 和 22 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 315 | 现货 | ||
2 mg | ¥ 452 | 现货 | ||
5 mg | ¥ 745 | 现货 | ||
10 mg | ¥ 1,180 | 现货 | ||
25 mg | ¥ 2,380 | 现货 | ||
50 mg | ¥ 3,560 | 现货 | ||
100 mg | ¥ 5,350 | 现货 | ||
500 mg | ¥ 10,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 818 | 现货 |
产品描述 | GSK1324726A (I-BET726) is a greatly specific inhibitor of BET family proteins for BRD2(IC50=41 nM), BRD3(IC50=31 nM), and BRD4 (IC50=22 nM). |
靶点活性 | BRD4:22 nM, BRD2:41 nM, BRD3:31 nM |
体外活性 | 在小鼠SK-N-AS和CHP-212模型中, GSK1324726A(15 mg/kg o.p.)抑制肿瘤生长,并下调MYCN 和 BCL2的表达.在小鼠感染性休克模型中,GSK1324726A(10 mg/kg i.v. )表现出有效的抗炎作用,并防止患病动物的死亡. |
体内活性 | 在神经母细胞瘤细胞系中,GSK1324726A抑制细胞生长并诱导细胞毒性。GSK1324726A能够调节MYC家族通路的基因表达,包括BCL2 和 MYCN的直接表达。 |
激酶实验 | Determination of BET Protein Binding Affinities to I-BET726: For determination of binding affinities to BET protein bromodomains, I-BET726 is titrated against truncates containing both BD1 and BD2 of BRD2 (10 nM), BRD3 (10 nM), and BRD4 (10 nM) in 50 mM HEPES pH7.5, 150 mM NaCl, 5% Glycerol, 1 mM DTT and 1 mM CHAPS in the presence of an Alexa 647 derivative (50 nM) of fluorescent ligand. After equilibrating for 1 h, the bromodomain protein: ligand interaction is detected using Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET) following the addition of 1.5 nM europium chelate labeled anti-6His antibody. Plates are read using an Envision Plate reader (λEX = 337 nm, λEM = 615 nm, λEM = 665 nm; dual dichroic = 400 nm & 630 nm). These data are fitted to a four parameter IC50 model using Graphit data analysis software. |
细胞实验 | Briefly, cells are seeded into 384-well or 96-well plates at a density optimized for 6 days of growth. The following day, T0 measurements are taken using CellTiter-Glo, CellTiter-Fluor, or CyQuant Direct, following the manufacturer's instructions. Plates are read on an Envision, Safire 2, or SpectraMax Gemini EM plate reader. Remaining plates are treated with DMSO or a titration of I-BET726. Cells are incubated for 6 days and developed as described above. Results are plotted as a percentage of the T0 value, normalized to 100%, versus concentration of compound. A 4-parameter equation is used to generate concentration response curves. Growth IC50 (gIC50) values are calculated at the mid-point of the growth window (between DMSO and T0 values). Ymin-T0 values are calculated by subtracting the T0 value (100%) from the Ymin value on the curve, and are a measure of net population cell growth or death.(Only for Reference) |
别名 | I-BET726 |
分子量 | 434.91 |
分子式 | C25H23ClN2O3 |
CAS No. | 1300031-52-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (183.9 mM)
Ethanol: 80 mg/mL (183.9 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.2993 mL | 11.4966 mL | 22.9933 mL | 57.4832 mL |
5 mM | 0.4599 mL | 2.2993 mL | 4.5987 mL | 11.4966 mL | |
10 mM | 0.2299 mL | 1.1497 mL | 2.2993 mL | 5.7483 mL | |
20 mM | 0.115 mL | 0.5748 mL | 1.1497 mL | 2.8742 mL | |
50 mM | 0.046 mL | 0.2299 mL | 0.4599 mL | 1.1497 mL | |
100 mM | 0.023 mL | 0.115 mL | 0.2299 mL | 0.5748 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GSK1324726A 1300031-52-0 Apoptosis Chromatin/Epigenetic Epigenetic Reader Domain GSK-1324726A I-BET-726 Inhibitor I-BET726 inhibit I-BET 726 inhibitor